Shakiba Mojdeh, Tuveson David A
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
Lustgarten Foundation Pancreatic Cancer Research Laboratory, Cold Spring Harbor, NY, USA.
Nat Immunol. 2025 May;26(5):678-691. doi: 10.1038/s41590-025-02134-6. Epub 2025 Apr 22.
Pancreatic ductal adenocarcinoma (PDAC) is one of the few cancers that has yet to benefit from immunotherapies. This is primarily a result of its characteristic 'cold' tumor microenvironment composed of cancer-associated fibroblasts (CAFs), a dense network of extracellular matrix and several immune cell types, the most abundant of which are the tumor-associated macrophages (TAMs). Advances in single-cell and spatial technologies have elucidated the vast functional heterogeneity of CAFs and TAMs, their symbiotic relationship and their cooperative role in the tumor microenvironment. In this Review, we provide an overview of the heterogeneity of CAFs and TAMs, how they establish an immunosuppressive microenvironment and their collaboration in the remodeling of the extracellular matrix. Finally, we examine why the impact of immunotherapy in PDAC has been limited and how a detailed molecular and spatial understanding of the combined role of CAFs and TAMs is paramount to the design of effective therapies.
胰腺导管腺癌(PDAC)是少数尚未从免疫疗法中获益的癌症之一。这主要是由于其具有特征性的“冷”肿瘤微环境,该微环境由癌症相关成纤维细胞(CAF)、致密的细胞外基质网络和几种免疫细胞类型组成,其中最丰富的是肿瘤相关巨噬细胞(TAM)。单细胞和空间技术的进展已经阐明了CAF和TAM的巨大功能异质性、它们的共生关系以及它们在肿瘤微环境中的协同作用。在本综述中,我们概述了CAF和TAM的异质性、它们如何建立免疫抑制微环境以及它们在细胞外基质重塑中的协作。最后,我们探讨了为什么免疫疗法在PDAC中的影响有限,以及对CAF和TAM联合作用的详细分子和空间理解对于有效疗法设计的至关重要性。